

## chain nodes :

1 2 3 4 5 6 7 15 16 23 24 25 26 39 46 47 48 49 50 54 55 57 58 61 62 73 74  
76 77 78 79

## ring nodes :

9 10 11 12 13 14 17 18 19 20 21 22 27 28 29 30 31 32 33 34 35 36 37 38 63 64  
65 66 67 68

## ring/chain nodes :

8

## chain bonds :

1-2 1-14 1-15 2-3 3-4 3-55 4-5 5-6 6-7 6-46 7-8 7-16 20-55 23-25 24-26 35-39 47-48  
49-50 57-58 61-62 62-63 73-74

## ring bonds :

9-10 9-14 10-11 11-12 12-13 13-14 17-18 17-22 18-19 19-20 20-21 21-22 27-28 27-32 28-29  
29-30 30-31 31-32 33-34 33-38 34-35 35-36 36-37 37-38 63-64 63-65 64-65 66-67 66-68  
67-68

## exact/norm bonds :

1-2 1-15 2-3 4-5 5-6 6-46 7-8 7-16 23-25 24-26 47-48 49-50 57-58 63-64 63-65 64-65  
66-67 66-68 67-68

## exact bonds :

1-14 3-4 3-55 6-7 20-55 35-39 61-62 62-63 73-74

## normalized bonds :

9-10 9-14 10-11 11-12 12-13 13-14 17-18 17-22 18-19 19-20 20-21 21-22 27-28 27-32 28-29  
29-30 30-31 31-32 33-34 33-38 34-35 35-36 36-37 37-38








G1:H,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,[\*1],[\*2],[\*3],[\*4]

G2:H,S,CN,Cb,[\*5],[\*6]

G3:H,O,S,N,[\*3],[\*4],[\*7],[\*8],[\*9],[\*10]

Match level :

1:CLASS2:CLASS3:CLASS4:CLASS5:CLASS6:CLASS7:CLASS8:CLASS9:Atom 10:Atom 11:Atom  
12:Atom 13:Atom 14:Atom 15:CLASS16:CLASS17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom  
23:CLASS24:CLASS25:CLASS26:CLASS27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom  
34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:CLASS46:CLASS47:CLASS48:CLASS49:CLASS  
50:CLASS54:CLASS55:CLASS56:Atom 57:CLASS58:CLASS61:CLASS62:CLASS63:Atom 64:Atom  
65:Atom 66:Atom 67:Atom 68:Atom 73:CLASS74:CLASS76:CLASS77:CLASS78:CLASS79:CLASS  
80:Atom 81:Atom 82:Atom 83:Atom



chain nodes :

1 2 3 4 5 6 7 14 15 22 23 24 25 38 45 46 47 48 49 53 54 56 57 60 61 72 73  
75 76 77 78 83 84 94 95 101 104 105 109

ring nodes :

8 9 10 11 12 13 16 17 18 19 20 21 26 27 28 29 30 31 32 33 34 35 36 37 62 63  
64 65 66 67 85 86 87 88 89 90 91 92 93 97 98

chain bonds :

1-2 1-13 1-14 2-3 2-83 3-4 3-54 4-5 5-6 5-84 6-7 6-45 7-15 7-109 19-54 22-24 23-25  
34-38 46-47 48-49 56-57 60-61 61-62 72-73 94-95 101-105 101-104

ring bonds :

8-9 8-13 9-10 10-11 11-12 12-13 16-17 16-21 17-18 18-19 19-20 20-21 26-27 26-31 27-28  
28-29 29-30 30-31 32-33 32-37 33-34 34-35 35-36 36-37 62-63 62-64 63-64 65-66 65-67  
66-67 85-86 85-98 86-87 87-88 88-98 89-90 89-97 90-93 91-92 91-93 92-97

exact/norm bonds :

1-2 1-14 2-3 5-6 6-45 7-15 7-109 22-24 23-25 46-47 48-49 56-57 62-63 62-64 63-64 65-66  
65-67 66-67 85-86 85-98 86-87 87-88 88-98 89-90 89-97 90-93 91-92 91-93 92-97 94-95  
101-105 101-104

exact bonds :

1-13 2-83 3-4 3-54 4-5 5-84 6-7 19-54 34-38 60-61 61-62 72-73

normalized bonds :

8-9 8-13 9-10 10-11 11-12 12-13 16-17 16-21 17-18 18-19 19-20 20-21 26-27 26-31 27-28  
28-29 29-30 30-31 32-33 32-37 33-34 34-35 35-36 36-37

G1:H,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,[\*1],[\*2],[\*3],[\*4]

G2:H,S,CN,Cb,[\*5],[\*6]

G3:H,O,S,N,[\*3],[\*4],[\*7],[\*8],[\*9],[\*10]





G4:H,X,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,[\*3],[\*4],[\*6],[\*11]

G5:[\*12],[\*13],[\*14]

Match level :

1:CLASS2:CLASS3:CLASS4:CLASS5:CLASS6:CLASS7:CLASS8:Atom 9:Atom 10:Atom 11:Atom  
12:Atom 13:Atom 14:CLASS15:CLASS16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:CLASS  
23:CLASS24:CLASS25:CLASS26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom  
34:Atom 35:Atom 36:Atom 37:Atom 38:CLASS45:CLASS46:CLASS47:CLASS48:CLASS49:CLASS  
53:CLASS54:CLASS55:Atom 56:CLASS57:CLASS60:CLASS61:CLASS62:Atom 63:Atom 64:Atom  
65:Atom 66:Atom 67:Atom 72:CLASS73:CLASS75:CLASS76:CLASS77:CLASS78:CLASS79:Atom  
80:Atom 81:Atom 82:Atom 83:CLASS84:CLASS85:CLASS86:CLASS87:CLASS88:CLASS89:CLASS  
90:CLASS91:CLASS92:CLASS93:CLASS94:CLASS95:CLASS97:Atom 98:CLASS101:CLASS104:CLASS  
105:CLASS109:CLASS





chain nodes :

1 2 3 4 5 6 7 15 16 23 24 25 26 39 46 47 48 49 50 54 55 57 58 61 62 73 74  
76 77 78 79 84 85

ring nodes :

9 10 11 12 13 14 17 18 19 20 21 22 27 28 29 30 31 32 33 34 35 36 37 38 63 64  
65 66 67 68

ring/chain nodes :

8

chain bonds :

1-2 1-14 1-15 2-3 2-84 3-4 3-55 4-5 5-6 5-85 6-7 6-46 7-8 7-16 20-55 23-25 24-26  
35-39 47-48 49-50 57-58 61-62 62-63 73-74

ring bonds :

9-10 9-14 10-11 11-12 12-13 13-14 17-18 17-22 18-19 19-20 20-21 21-22 27-28 27-32 28-29  
29-30 30-31 31-32 33-34 33-38 34-35 35-36 36-37 37-38 63-64 63-65 64-65 66-67 66-68  
67-68

exact/norm bonds :

1-2 1-15 2-3 5-6 6-46 7-8 7-16 23-25 24-26 47-48 49-50 57-58 63-64 63-65 64-65 66-67  
66-68 67-68

exact bonds :

1-14 2-84 3-4 3-55 4-5 5-85 6-7 20-55 35-39 61-62 62-63 73-74

normalized bonds :

9-10 9-14 10-11 11-12 12-13 13-14 17-18 17-22 18-19 19-20 20-21 21-22 27-28 27-32 28-29  
29-30 30-31 31-32 33-34 33-38 34-35 35-36 36-37 37-38

G1:H,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,[\*1],[\*2],[\*3],[\*4]

G2:H,S,CN,Cb,[\*5],[\*6]

G3:H,O,S,N,[\*3],[\*4],[\*7],[\*8],[\*9],[\*10]

Match level :

1:CLASS2:CLASS3:CLASS4:CLASS5:CLASS6:CLASS7:CLASS8:CLASS9:Atom 10:Atom 11:Atom  
12:Atom 13:Atom 14:Atom 15:CLASS16:CLASS17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom  
23:CLASS24:CLASS25:CLASS26:CLASS27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom  
34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:CLASS46:CLASS47:CLASS48:CLASS49:CLASS  
50:CLASS54:CLASS55:CLASS56:Atom 57:CLASS58:CLASS61:CLASS62:CLASS63:Atom 64:Atom  
65:Atom 66:Atom 67:Atom 68:Atom 73:CLASS74:CLASS76:CLASS77:CLASS78:CLASS79:CLASS  
80:Atom 81:Atom 82:Atom 83:Atom 84:CLASS85:CLASS

Connecting via winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau129pxo

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 5	AUG 30	CA(SM)/Caplus(SM) Austrian patent law changes
NEWS 6	SEP 21	CA/Caplus fields enhanced with simultaneous left and right truncation
NEWS 7	SEP 25	CA(SM)/Caplus(SM) display of CA Lexicon enhanced
NEWS 8	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 9	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 10	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 11	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS 12	OCT 19	E-mail format enhanced
NEWS 13	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS 14	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 15	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 16	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 17	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 18	NOV 10	CA/Caplus F-Term thesaurus enhanced
NEWS 19	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 20	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 21	NOV 20	CA/Caplus to MARPAT accession number crossover limit increased to 50,000
NEWS 22	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 23	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 24	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 25	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 26	DEC 18	CA/Caplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 27	DEC 18	CA/Caplus patent kind codes updated
NEWS 28	DEC 18	MARPAT to CA/Caplus accession number crossover limit increased to 50,000
NEWS 29	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 30	DEC 27	CA/Caplus enhanced with more pre-1907 records
NEWS EXPRESS	NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.	

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 18:23:59 ON 04 JAN 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 18:24:13 ON 04 JAN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 JAN 2007 HIGHEST RN 916687-76-8

DICTIONARY FILE UPDATES: 3 JAN 2007 HIGHEST RN 916687-76-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

=>

Uploading C:\Program Files\Stnexp\Queries\10563538.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 18:47:15 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 17447 TO ITERATE

11.5% PROCESSED 2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

16 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 341031 TO 356849  
PROJECTED ANSWERS: 2083 TO 3499

L2 16 SEA SSS SAM L1

=> search l1

ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.  
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full  
FULL SEARCH INITIATED 18:47:22 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 348855 TO ITERATE

98.9% PROCESSED 344924 ITERATIONS  
100.0% PROCESSED 348855 ITERATIONS  
SEARCH TIME: 00.00.17

2667 ANSWERS

2674 ANSWERS

L3 2674 SEA SSS FUL L1

=>

=>

Uploading C:\Program Files\Stnexp\Queries\10563538c.str

L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS

L4 STR

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.

=> s l4

SAMPLE SEARCH INITIATED 19:11:30 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 16926 TO ITERATE

11.8% PROCESSED 2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

2 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 330729 TO 346311  
PROJECTED ANSWERS: 92 TO 584

L5 2 SEA SSS SAM L4

=> search l4

ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.  
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full

FULL SEARCH INITIATED 19:11:38 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 338497 TO ITERATE

100.0% PROCESSED 338497 ITERATIONS 428 ANSWERS  
SEARCH TIME: 00.00.17

L6 428 SEA SSS FUL L4

=>  
Uploading C:\Program Files\Stnexp\Queries\10563538d.str

L7 STRUCTURE UPLOADED

=> d 17  
L7 HAS NO ANSWERS  
L7 STR  
\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.

=> s 17  
SAMPLE SEARCH INITIATED 19:14:18 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 930 TO ITERATE

100.0% PROCESSED 930 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 16771 TO 20429  
PROJECTED ANSWERS: 0 TO 0

L8 0 SEA SSS SAM L7

=> search 17  
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.  
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full  
FULL SEARCH INITIATED 19:14:26 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 18370 TO ITERATE

100.0% PROCESSED 18370 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.03

L9 0 SEA SSS FUL L7

=>  
Uploading C:\Program Files\Stnexp\Queries\10563538x.str

L10 STRUCTURE UPLOADED

=> d 110  
L10 HAS NO ANSWERS  
L10 STR  
\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.

=> s 110  
SAMPLE SEARCH INITIATED 19:16:55 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 17447 TO ITERATE

11.5% PROCESSED 2000 ITERATIONS 3 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 341031 TO 356849  
PROJECTED ANSWERS: 217 TO 829

L11 3 SEA SSS SAM L10

=> search l10  
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:  
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full  
FULL SEARCH INITIATED 19:17:01 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 348855 TO ITERATE

98.9% PROCESSED 344901 ITERATIONS 435 ANSWERS

100.0% PROCESSED 348855 ITERATIONS 435 ANSWERS  
SEARCH TIME: 00.00.17

L12 435 SEA SSS FUL L10

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	726.65	726.86

FILE 'CAPLUS' ENTERED AT 19:17:24 ON 04 JAN 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Jan 2007 VOL 146 ISS 2  
FILE LAST UPDATED: 3 Jan 2007 (20070103/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l12  
L13 10 L12

=> d l13 fbib ab hitstr 1-10

L13 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:1041179 CAPLUS  
 DN 145:419471  
 TI Preparation of peptide 1,2-ethylenediamine derivatives for the treatment of Alzheimer's disease  
 IN Eickmeier, Christian; Fuchs, Klaus; Peters, Stefan; Dorner-Ciossek, Cornelia; Heine, Niklas; Handschuh, Sandra; Klinder, Klaus; Kostka, Marcus  
 PA Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG  
 SO PCT Int. Appl., 325pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006103038	A1	20061005	WO 2006-EP2769	20060327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006223759	A1	20061005	EP 2005-6939	A 20050330
			US 2006-278059	20060330
			EP 2005-6939	A 20050330

OS MARPAT 145:419471  
 AB The invention relates to substituted 1,2-ethylenediamines I [A is aryl or heteroaryl which may be substituted; B is C1-4-alkylene or oxyalkylene; R1, R2, R5-R9 are H, (un)substituted alkyl, (hetero)aryl, etc. (but R2 is not H); R3, R4 are H, alkyl, F, CF3, CHF2, CH2F; X1-X4 are N, C or substituted carbon (0-3 of these groups are N)], including tautomers, diastereomers, enantiomers, and salts, and their use in the treatment of Alzheimer's disease (AD) and similar diseases. Thus, peptide II was prepared by a multistep sequence using reactants which include di-Me 5-aminoisophthalate, (R)-1-phenylethylamine, and protected amino acids. Comps. of the invention listed in a table have IC50 values < 30  $\mu$ M in the  $\beta$ -secretase inhibition assay.


IT 911786-30-6P 911786-31-7P 911786-32-8P  
 911786-33-9P 911786-34-0P 911786-35-1P  
 911786-36-2P 911786-37-3P 911786-38-4P  
 911786-39-5P 911786-40-8P 911786-41-9P  
 911786-42-0P 911786-43-1P 911786-44-2P  
 911786-45-3P 911786-46-4P 911786-47-5P  
 911786-48-6P 911786-49-7P 911786-50-0P  
 911786-51-1P 911786-52-2P 911786-53-3P  
 911786-54-4P 911786-55-5P 911786-56-6P  
 911786-57-7P 911786-58-8P 911786-59-9P  
 911786-60-2P 911786-61-3P 911786-62-4P  
 911786-63-5P 911786-64-6P 911786-65-7P  
 911786-66-8P 911786-67-9P 911786-68-0P  
 911786-69-1P 911786-70-4P 911786-71-5P  
 911786-72-6P 911786-73-7P 911786-74-8P  
 911786-75-9P 911786-76-0P 911786-77-1P  
 911786-78-2P 911786-79-3P 911786-80-6P  
 911786-81-7P 911786-82-8P 911786-83-9P



911786-84-0P 911786-85-1P 911786-86-2P  
911786-87-3P 911786-88-4P 911786-89-5P  
911786-90-8P 911786-91-9P 911786-92-0P  
911786-93-1P 911786-94-2P 911786-95-3P  
911786-96-4P 911786-97-5P 911786-98-6P  
911787-01-4P 911787-02-5P 911787-05-8P  
911787-06-9P 911787-07-0P 911787-08-1P  
911787-15-0P 911787-19-4P 911787-20-7P  
911787-21-8P 911787-22-9P 911787-27-4P  
911787-28-5P 911787-29-6P 911787-30-9P  
911787-35-4P 911787-38-7P 911787-39-8P  
911787-40-1P 911787-41-2P 911787-42-3P  
911787-43-4P 911787-44-5P 911787-45-6P  
911787-46-7P 911787-47-8P 911787-49-0P  
911787-50-3P 911787-51-4P 911787-52-5P  
911787-55-8P 911787-56-9P 911787-57-0P  
911787-58-1P 911787-59-2P 911787-60-5P  
911787-61-6P 911787-62-7P 911787-63-8P  
911787-64-9P 911787-65-0P 911787-66-1P  
911787-67-2P 911787-68-3P 911787-69-4P  
911787-70-7P 911787-71-8P 911787-72-9P  
911787-73-0P 911787-74-1P 911787-75-2P  
911787-76-3P 911787-77-4P 911787-78-5P  
911787-79-6P 911787-80-9P 911787-81-0P  
911787-82-1P 911787-83-2P 911787-84-3P  
911787-85-4P 911787-86-5P 911787-87-6P  
911787-88-7P 911787-89-8P 911787-90-1P  
911787-91-2P 911787-92-3P 911787-93-4P  
911787-94-5P 911787-95-6P 911787-96-7P  
911787-97-8P 911787-98-9P 911787-99-0P  
911788-00-6P 911788-01-7P 911788-02-8P  
911788-03-9P 911788-04-0P 911788-05-1P  
911788-06-2P 911788-07-3P 911788-08-4P  
911788-09-5P 911788-10-8P 911788-11-9P  
911788-12-0P 911788-13-1P 911788-14-2P  
911788-15-3P 911788-16-4P 911788-17-5P  
911788-18-6P 911788-19-7P 911788-20-0P  
911788-21-1P 911788-22-2P 911788-23-3P  
911788-24-4P 911788-25-5P 911788-26-6P  
911788-27-7P 911788-28-8P 911788-29-9P  
911788-30-2P 911788-31-3P 911788-32-4P  
911788-38-0P 911788-39-1P 911788-40-4P  
911788-55-1P 911788-71-1P 911788-72-2P  
911788-73-3P 911788-74-4P 911789-28-1P  
911789-29-2P 911789-33-8P 911789-34-9P  
911789-35-0P 911789-36-1P 911789-37-2P  
911789-38-3P 911789-39-4P 911789-40-7P  
911789-41-8P 911789-42-9P 911789-47-4P  
911789-48-5P 911789-49-6P 911789-52-1P  
911789-55-4P 911789-56-5P 911789-57-6P  
911789-58-7P 911789-61-2P 911789-62-3P  
911789-63-4P 911789-64-5P 911789-65-6P  
911789-71-4P 911789-72-5P 911789-73-6P  
911789-79-2P 911789-80-5P 911789-81-6P  
911789-82-7P 911789-83-8P 911789-84-9P  
911789-85-0P 911789-86-1P 911789-87-2P  
911789-88-3P 911789-89-4P 911789-90-7P  
911789-96-3P 911790-01-7P 911790-02-8P  
911790-03-9P 911790-04-0P 911790-05-1P  
911790-06-2P 911790-07-3P 911790-20-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU






RN 911786-33-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911786-34-0 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1R)-1-phenylpropyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl-  
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-35-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1S)-1-phenylpropyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl-  
 (9CI) (CA INDEX NAME)


phenylpropyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-36-2 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[1-(3-pyridinyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-37-3 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[1-(4-pyridinyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN	911786-38-4	CAPLUS
CN	L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[1-(2-pyridinyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.



RN	911786-39-5	CAPLUS
CN	L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[1-(3-thienyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)	


Absolute stereochemistry.



RN 911786-40-8 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[2-


phenylethyl)amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911786-41-9 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(4-chlorophenyl)propyl]amino]carbonyl]-5-  
[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-  
ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

—C]

RN 911786-42-0 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[1-[[4-  
(trifluoromethoxy)phenyl]methyl]cyclopropyl]amino]carbonyl]benzoyl]amino]-  
3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-43-1 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[2-phenyl-1-(2-pyridinyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-44-2 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[2-methyl-2-phenylpropyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-45-3 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[[3-[methyl(methylsulfonyl)amino]-5-[[[2-[4-(1-pyrrolidinylmethyl)phenyl]ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Pr-i


—NH<sub>2</sub>

RN 911786-46-4 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[[3-[[[1,1'-biphenyl]-4-ylethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 911786-47-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-methoxyphenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911786-48-6 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-bromophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-49-7 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1R)-1-(2-

naphthalenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—NH<sub>2</sub>


RN 911786-50-0 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[methyl[(1S)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-51-1 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[methyl[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-52-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[methyl(methylsulfonyl)amino]-5-[[[(1-phenylcyclopropyl)amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911786-53-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-54-4 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[1-(2-methoxyphenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-55-5 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[1-methyl-3-phenylpropyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-56-6 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1R)-1-(4-methylphenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-57-7 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[2,2,2-trifluoro-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911786-58-8 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[2,2,2-trifluoro-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-59-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[1,3-benzodioxol-5-ylmethyl]amino]carbonyl]-5-[[2,2,2-trifluoro-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-60-2 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(2,6-difluorophenyl)methyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-61-3 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[3-[[[(2-fluorophenyl)methyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-62-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(3-methylphenyl)methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911786-63-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(phenylmethyl)propyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-64-6 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B


—NH<sub>2</sub>t

—Pr-i

RN 911786-65-7 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[2-[3-(trifluoromethyl)phenyl]ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-66-8 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[1-(1-methyl-1H-pyrazol-4-yl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)




Absolute stereochemistry.




RN 911786-67-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[1-(1-ethyl-1H-pyrazol-3-yl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-68-0 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(3-hydroxyphenyl)methyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-69-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(3-hydroxy-4-methoxyphenyl)methyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911786-70-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(5-cyclopropyl-1H-pyrazol-3-yl)methyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-71-5 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1H-pyrazol-3-yl)methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-72-6 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(5-methyl-1H-1,2,4-triazol-3-yl)methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-73-7 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(3,4-difluorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-74-8 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[methyl(2-phenylethyl)amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-75-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[ethyl(phenylmethyl)amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-76-0 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(3-amino-3-oxopropyl)(phenylmethyl)amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-77-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1-methylethyl)(phenylmethyl)amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-78-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(4-bromophenyl)methyl]methylamino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911786-79-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[methyl(3-pyridinylmethyl)amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-80-6 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(2-cyanoethyl)(phenylmethyl)amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-81-7 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(2-phenylethyl)propylamino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-82-8 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(2-cyanoethyl)(2-phenylethyl)amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-83-9 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[1-(1-methyl-1H-pyrazol-3-yl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-84-0 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[methyl[(phenylmethyl)sulfonyl]amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 911786-85-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl(3-pyridinylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-86-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[(ethylsulfonyl)methylamino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-87-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(dimethylamino)sulfonyl]methylamino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-88-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl(4-morpholinylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911786-89-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl(phenylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-90-8 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl[(1-methylethyl)sulfonyl]amino]-5-

[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-91-9 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-fluorophenyl)ethyl]amino]carbonyl]-5-[methyl(phenylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-92-0 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[methyl(phenylsulfonyl)amino]-5-[[[1-(1-methyl-1H-pyrazol-4-yl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-93-1 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[methyl(phenylsulfonyl)amino]-5-[[[(1H-pyrazol-3-ylmethyl)amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911786-94-2 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-fluorophenyl)ethyl]amino]carbonyl]-5-[[[(4-fluorophenyl)sulfonyl]methylamino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-95-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(4-fluorophenyl)sulfonyl]methylamino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-96-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(4-fluorophenyl)sulfonyl]methylamino]-5-[[[(2-thiazolylmethyl)amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-97-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(4-fluorophenyl)sulfonyl]methylamino]-5-[[[1-(1-methyl-1H-pyrazol-4-yl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911786-98-6 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[4-fluorophenyl)sulfonyl]methylamino]-5-[[[(1H-pyrazol-3-yl)methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911787-01-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl[(phenylmethyl)sulfonyl]amino]-5-[[[1-(3-pyridinyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911787-02-5 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-bromophenyl)ethyl]amino]carbonyl]-5-[methyl[(phenylmethyl)sulfonyl]amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911787-05-8 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(4-bromophenyl)methyl]sulfonyl]methylamino]-5-[[[1-(3-pyridinyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911787-06-9 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-bromophenyl)ethyl]amino]carbonyl]-5-[[[(4-bromophenyl)methyl]sulfonyl]methylamino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911787-07-0 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[ethyl(methylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-08-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[ethyl(methylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 911787-07-0  
 CMF C38 H52 N6 O6 S


Absolute stereochemistry.






CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 911787-15-0 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-[4-(trifluoromethyl)phenyl]propyl]-L-alanyl-N-ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-19-4 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-2-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-20-7 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911787-21-8 CAPLUS  
 CN 1,3-Benzenedicarboxamide, N-[(1S)-1-[[[(1S)-2-[[1-[(ethylamino)carbonyl]-3,3,3-trifluoropropyl]amino]-1-methyl-2-oxoethyl]amino]methyl]-2-phenylethyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911787-22-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1S)-1-[[[(1S)-1-[[[(1S)-1-[(ethylamino)carbonyl]-2-methylpropyl]amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911787-27-4 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-bromophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911787-28-5 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-bromophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 911787-27-4


CMF C35 H45 Br N6 O6 S

Absolute stereochemistry.



CM 2


CRN 76-05-1  
CMF C2 H F3 O2




RN 911787-29-6 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-bromophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-(2,2,2-trifluoroethyl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 911787-30-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-bromophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-(2,2,2-trifluoroethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 911787-29-6  
 CMF C37 H46 Br F3 N6 O6 S

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 911787-35-4 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911787-38-7 CAPLUS  
CN L-Valinamide, (2S)-2-cyclopropyl-N-[2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]glycyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-39-8 CAPLUS  
CN L-Valinamide, (2S)-2-cyclopropyl-N-[2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]glycyl-N-ethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 911787-38-7

CMF C39 H52 N6 O6 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 911787-40-1 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[methyl(methylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-norvalyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911787-41-2 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[methyl(methylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-norvalyl-N-


ethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 911787-40-1

CMF C39 H54 N6 O6 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 911787-42-3 CAPLUS

CN L-Valinamide, 3-cyano-N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-43-4 CAPLUS



CN 1,3-Benzenedicarboxamide, N-[(1S)-1-[[[(1S)-1-[[[(1S)-1-[(ethylamino)carbonyl]-2-methylpropyl]amino]carbonyl]-3,3,3-trifluoropropyl]amino]methyl]-2-phenylethyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911787-44-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1S)-1-[[[(1S)-1-[[[(1S)-1-[(ethylamino)carbonyl]-2-methylpropyl]amino]carbonyl]-3-phenylpropyl]amino]methyl]-2-phenylethyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911787-45-6 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[[3-[methyl(1-piperidinylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-46-7 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl[(4-methyl-1-piperidiny)sulfonyl]amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-47-8 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl(1-pyrrolidiny)sulfonyl]amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-49-0 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[(difluoromethyl)(methylsulfonyl)amino]-5-[[[(1R)-1-(4-fluorophenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-50-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[(difluoromethyl)(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-51-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[(difluoromethyl)(methylsulfonyl)amino]-5-[[2-thiazolylmethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-52-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[(phenylmethyl)amino]carbonyl]benzoyl]amino]propyl]]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-55-8 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[methyl(phenylmethyl)amino]carbonyl]benzoyl]amino]-3-phenylpropyl]]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-56-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[(phenylmethyl)propylamino]carbonyl]benzoyl]amino]propyl]]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-57-0 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[methyl[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911787-58-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-bromophenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911787-59-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[1-[(3-hydroxy-4-methylphenyl)methyl]propyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



—Me


RN 911787-60-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[2-phenyl-1-(phenylmethyl)ethyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-61-6 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-methylphenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-62-7 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[(1R)-1-phenylpropyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911787-63-8 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(2-naphthalenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—NH<sub>2</sub>


RN 911787-64-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(3,4-dihydroxyphenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911787-65-0 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(1H-indol-3-yl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




—NH<sub>2</sub>Et

—Pr-i


RN 911787-66-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[2-(2-pyridinyl)ethyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-67-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(2-chlorophenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911787-68-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(2-methoxyphenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-69-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(3-methoxyphenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)



zoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—NH<sub>2</sub>

—Pr-i


RN 911787-70-7 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911787-71-8 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(4-bromophenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—NHet

—Pr-i

RN 911787-72-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(4-chlorophenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—NHet

—Pr-i

RN 911787-73-0 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(4-hydroxyphenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B


—NHET

— Pr-i

RN 911787-74-1 CAPLUS

L-Valinamide, N-[[[3-[[[2-(4-methylphenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B

— NHET


— pr-i

RN 911787-75-2 CAPLUS


L-Valinamide, N-[[[2S]-2-[[[3-[[[2-[4-(aminosulfonyl)phenyl]ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl]-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 911787-76-3 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(4-nitrophenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 911787-77-4 CAPLUS  
CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[2-[3-(trifluoromethyl)phenyl]ethyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—NH<sub>2</sub>t

—Pr-i

RN 911787-78-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(3-chlorophenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—NH<sub>2</sub>t

—Pr-i


RN 911787-79-6 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[2-(2-thienyl)ethyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-80-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(2-chloro-6-fluorophenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-81-0 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(2,6-dichlorophenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-82-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(2-ethoxyphenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-83-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(3,5-dimethoxyphenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911787-84-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(4-ethoxyphenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B


—NH<sub>2</sub>

—Pr-i

RN 911787-85-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(7-methyl-1H-indol-3-yl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—NH<sub>2</sub>

—Pr-i

RN 911787-86-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(3-fluorophenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—NH<sub>2</sub>

RN 911787-87-6 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(4-fluorophenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.




PAGE 1-B

—NHEt


RN	911787-88-7	CAPLUS
CN	L-Valinamide, N-[[[2S)-2-[[[3-[[[2-(3-bromo-4-methoxyphenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.




RN	911787-89-8	CAPLUS
CN	L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[2-(3-pyridinyl)ethyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.



RN 911787-90-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(2,4-dimethylphenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911787-91-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(2-naphthalenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—Pr-i

—NH<sub>2</sub>

RN 911787-92-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[2-[4-(trifluoromethyl)phenyl]ethyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—NH<sub>2</sub>t

—Pr-i


RN 911787-93-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(3,4-difluorophenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-94-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(2,4-difluorophenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-95-6 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(2,5-difluorophenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-96-7 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(3,5-difluorophenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-97-8 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(2,6-difluorophenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-98-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(3,5-dimethyl-4-isoxazolyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-99-0 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911788-00-6 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-[4-(diethylamino)phenyl]ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B

—NH<sub>2</sub>

—Pr-i

RN 911788-01-7 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(2-furanyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911788-02-8 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[2-[2-(trifluoromethoxy)phenyl]ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


l]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911788-03-9 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-[[[1-(1,3-dimethyl-1H-pyrazol-4-yl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911788-04-0 CAPLUS  
CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[1-[3-(trifluoromethyl)phenyl]ethyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911788-05-1 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-[[[1-(1-methyl-1H-pyrazol-5-yl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911788-06-2 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[1-(1-methyl-1H-pyrazol-3-yl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911788-07-3 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[1-(1-ethyl-1H-pyrazol-3-yl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911788-08-4 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[1-(naphthalenylmethyl)amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 911788-09-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911788-10-8 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(2-fluorophenyl)methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911788-11-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(2-chlorophenyl)methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911788-12-0 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(2,4-dichlorophenyl)methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911788-13-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(2-methylphenyl)methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911788-14-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(3-fluorophenyl)methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911788-15-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(3-methoxyphenyl)methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911788-16-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(3-methylphenyl)methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911788-17-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(2,6-difluorophenyl)methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911788-18-6 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(3,5-dimethylphenyl)methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911788-19-7 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(2,3-dihydro-5-benzofuranyl)methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911788-20-0 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911788-21-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[4-(1H-pyrazol-1-yl)phenyl]methyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—NH<sub>2</sub>t

—Pr-i


RN 911788-22-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-(1H-imidazol-4-yl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911788-23-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[1-[2-(trifluoromethyl)phenyl]ethyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911788-24-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[1-[4-(trifluoromethyl)phenyl]ethyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 911788-25-5 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(3,4-dichlorophenyl)methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911788-26-6 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(4-chlorophenyl)methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911788-27-7 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[4-(1-methylethyl)phenyl]methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911788-28-8 CAPLUS

L-Valinamide, N-[(2S)-2-[[[3-[[[(3,5-difluorophenyl)methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911788-29-9 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[4-(dimethylamino)phenyl]methyl]amino]carbo  
nyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.




PAGE 1-B

—NHEt

RN 911788-30-2 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[3-[[[5-benzofuranylmethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911788-31-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911788-32-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(2,5-difluorophenyl)methyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911788-38-0 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 911788-39-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[(1S)-1-phenylethyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.




RN 911788-40-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-[[4-[[dimethylamino]carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 911788-55-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-(3,5-difluorophenyl)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911788-71-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-(4-nitrophenyl)propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911788-72-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-(4-bromophenyl)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911788-73-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-(4-aminophenyl)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911788-74-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-(4-chlorophenyl)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911789-28-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-bromo-5-[[[(1R)-1-(4-fluorophenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 911789-29-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-bromo-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[[4-[[[(dimethylamino)carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






RN 911789-33-8 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-(benzoylamino)-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911789-34-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[(phenylacetyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911789-35-0 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-(acetylmethylamino)-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911789-36-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-(methylamino)-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911789-37-2 CAPLUS  
 CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-β-alanyl-3-[[[(1R)-1-(4-bromophenyl)ethyl]amino]carbonyl]-5-(methylamino)benzoyl-L-phenylalanyl-ψ(CH<sub>2</sub>-NH)-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911789-38-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-bromophenyl)ethyl]amino]carbonyl]-5-[(3-methoxy-1-oxopropyl)methylamino]benzoyl]amino]-3-phenylpropyl]-L-



RN 911789-41-8 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-bromophenyl)ethyl]amino]carbonyl]-5-[(methoxycarbonyl)methylamino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911789-42-9 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[(methylsulfonyl)phenylamino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911789-47-4 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[(4-fluorophenyl)(methylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 911789-48-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[(4-fluorophenyl)(4-morpholinylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911789-49-6 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-chloro-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911789-52-1 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-chloro-5-[[[(1R)-1-(4-fluorophenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911789-55-4 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-chloro-5-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911789-56-5 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[3-chloro-5-[[[(2R)-2-(4-chlorophenyl)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911789-57-6 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[[3-chloro-5-[[[1-(3-thienyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911789-58-7 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[[3-chloro-5-[[[(1R)-1-phenylpropyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911789-61-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[[3-chloro-5-[[[1-(3-pyridinyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911789-62-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-chloro-5-[[[(1R)-1-(4-methoxyphenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911789-63-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-chloro-5-[[[(1-methyl-3-phenylpropyl)amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911789-64-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-chloro-5-[[[1-(2-methoxyphenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911789-65-6 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[(1R)-1-phenylethyl]amino]carbonyl]-5-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911789-71-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911789-72-5 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-methoxyphenyl)ethyl]amino]carbonyl]-5-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911789-73-6 CAPLUS

CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[(1R)-1-phenylethyl]amino]carbonyl]-5-(tetrahydro-1,1-dioxido-2H-1,2,6-thiadiazin-2-yl)benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911789-79-2 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-(tetrahydro-1,1-dioxido-2H-1,2,6-thiadiazin-2-yl)benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911789-80-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-methoxyphenyl)ethyl]amino]carbonyl]-5-(tetrahydro-1,1-dioxo-2H-1,2,6-thiadiazin-2-yl)benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911789-81-6 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-fluorophenyl)ethyl]amino]carbonyl]-5-(tetrahydro-1,1-dioxo-2H-1,2,6-thiadiazin-2-yl)benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911789-82-7 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1-methyl-1-phenylethyl)amino]carbonyl]-5-(tetrahydro-1,1-dioxido-2H-1,2,6-thiadiazin-2-yl)benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911789-83-8 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[1-(1-methyl-1H-pyrazol-4-yl)ethyl]amino]carbonyl]-5-(tetrahydro-1,1-dioxido-2H-1,2,6-thiadiazin-2-yl)benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911789-84-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-(tetrahydro-1,1-dioxido-2H-1,2,6-thiadiazin-2-yl)-5-[[2-thiazolylmethyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 911789-85-0 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-bromophenyl)ethyl]amino]carbonyl]-5-(tetrahydro-1,1-dioxido-2H-1,2,6-thiadiazin-2-yl)benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911789-86-1 CAPLUS

CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[(3-pyridinylmethyl)amino]carbonyl]-5-(tetrahydro-1,1-dioxido-2H-1,2,6-thiadiazin-2-yl)benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911789-87-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1S)-2-[[[(1S)-2-[[1-[(ethylamino)carbonyl]propyl]amino]-1-methyl-2-oxoethyl]amino]-1-(phenylmethyl)ethyl]-N'-[(1R)-1-(4-fluorophenyl)ethyl]-5-(tetrahydro-1,1-dioxido-2H-1,2,6-thiadiazin-2-yl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911789-88-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1S)-2-[[[(1S)-2-[[1-[(ethylamino)carbonyl]propyl]amino]-1-methyl-2-oxoethyl]amino]-1-(phenylmethyl)ethyl]-N'-[(1-methyl-1-phenylethyl)-5-(tetrahydro-1,1-dioxido-2H-1,2,6-thiadiazin-2-yl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911789-89-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1S)-2-[[[(1S)-2-[[1-[(ethylamino)carbonyl]propyl]amino]-1-methyl-2-oxoethyl]amino]-1-(phenylmethyl)ethyl]-N'-[1-(1-methyl-1H-pyrazol-4-yl)ethyl]-5-(tetrahydro-1,1-dioxido-2H-1,2,6-thiadiazin-2-yl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911789-90-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1S)-2-[[[(1S)-2-[[1-  
[(ethylamino)carbonyl]propyl]amino]-1-methyl-2-oxoethyl]amino]-1-  
(phenylmethyl)ethyl]-5-(tetrahydro-1,1-dioxido-2H-1,2,6-thiadiazin-2-yl)-  
N'-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911789-96-3 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl  
]-5-[[[(dimethylamino)sulfonyl]methylamino]benzoyl]amino]-3-phenylpropyl]-L-  
alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911790-01-7 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(dimethylamino)sulfonyl]methylamino]-5-[[[(1R)-1-(4-fluorophenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911790-02-8 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(dimethylamino)sulfonyl]methylamino]-5-[[[(1R)-1-(4-methoxyphenyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911790-03-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(dimethylamino)sulfonyl]methylamino]-5-[[[(1R)-1-phenylpropyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911790-04-0 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(dimethylamino)sulfonyl]methylamino]-5-[[[(1-methyl-1-phenylethyl)amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911790-05-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(dimethylamino)sulfonyl]methylamino]-5-[[[(1-(2-pyridinyl)ethyl)amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911790-06-2 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(dimethylamino)sulfonyl]methylamino]-5-[[[1-(3-pyridinyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911790-07-3 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(dimethylamino)sulfonyl]methylamino]-5-[[[1-(3-thienyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911790-20-0 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(4-morpholinylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT	911790-26-6P	911790-27-7P	911790-28-8P
	911790-29-9P	911790-30-2P	911790-31-3P
	911790-32-4P	911790-33-5P	911790-39-1P
	911790-40-4P	911790-41-5P	911790-42-6P
	911790-43-7P	911790-44-8P	911790-45-9P
	911790-46-0P	911790-59-5P	911790-66-4P
	911790-67-5P	911790-68-6P	911790-69-7P
	911790-75-5P	911790-76-6P	911790-87-9P
	911790-88-0P	911790-89-1P	911790-90-4P
	911790-91-5P	911790-92-6P	911790-93-7P
	911790-94-8P	911790-95-9P	911790-96-0P
	911790-97-1P	911790-98-2P	911790-99-3P
	911791-00-9P	911791-01-0P	911791-02-1P
	911791-03-2P	911791-04-3P	911791-10-1P
	911791-11-2P	911791-12-3P	911791-13-4P
	911791-14-5P	911791-15-6P	911791-16-7P
	911791-17-8P	911791-18-9P	911791-19-0P
	911791-20-3P	911791-21-4P	911791-22-5P
	911791-23-6P	911791-24-7P	911791-25-8P
	911791-26-9P	911791-27-0P	911791-28-1P
	911791-29-2P	911791-30-5P	911791-31-6P
	911791-32-7P	911791-33-8P	911791-34-9P
	911791-35-0P	911791-36-1P	911791-37-2P
	911791-38-3P	911791-39-4P	911791-40-7P
	911791-41-8P	911791-42-9P	911791-43-0P
	911791-44-1P	911791-45-2P	911791-46-3P
	911791-50-9P	911791-51-0P	911791-52-1P
	911791-53-2P	911791-54-3P	911791-55-4P
	911791-56-5P	911791-57-6P	911791-58-7P
	911791-59-8P	911791-60-1P	911791-61-2P
	911791-62-3P	911791-63-4P	911791-64-5P
	911791-65-6P	911791-67-8P	911791-69-0P
	911791-70-3P	911791-75-8P	911791-76-9P
	911791-77-0P	911791-78-1P	911791-79-2P
	911791-84-9P	911791-87-2P	911791-90-7P
	911791-92-9P	911791-95-2P	911791-98-5P
	911792-00-2P	911792-02-4P	911792-05-7P
	911792-08-0P	911792-09-1P	911792-12-6P
	911792-20-6P	911792-21-7P	911792-22-8P
	911792-23-9P	911792-28-4P	911792-31-9P
	911792-32-0P	911823-02-4P	


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptide ethylenediamine derivs. for treatment of Alzheimer's disease)

RN 911790-26-6 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-fluorophenyl)ethyl]amino]carbonyl]-5-[methyl(4-morpholinylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911790-27-7 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-methoxyphenyl)ethyl]amino]carbonyl]-5-[methyl(4-morpholinylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911790-28-8 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[methyl(4-morpholinylsulfonyl)amino]-5-[[[(1R)-1-phenylpropyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 911790-29-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl(4-morpholinylsulfonyl)amino]-5-[[[1-methyl-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911790-30-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl(4-morpholinylsulfonyl)amino]-5-[[[1-(2-pyridinyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911790-31-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl(4-morpholinylsulfonyl)amino]-5-[[[1-(3-


pyridinyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911790-32-4 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-[methyl(4-morpholinylsulfonyl)amino]-5-[[[1-(3-thienyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911790-33-5 CAPLUS  
CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[(1R)-1-phenylethyl]amino]carbonyl]-5-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911790-39-1 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-(tetrahydro-1,1-dioxo-2H-1,2-thiazin-2-yl)benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911790-40-4 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[(2-thiazolylmethyl)amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911790-41-5 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1-methyl-2-phenoxyethyl)amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911790-42-6 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[1,1-dimethyl-2-(2-methylphenoxy)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911790-43-7 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(1,1-dimethyl-2-phenoxyethyl)amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 911790-44-8 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-[4-(2-amino-2-oxoethyl)phenoxy]-1,1-dimethylethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 911790-45-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[2-[4-(acetylamino)phenoxy]-1,1-

dimethylethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino  
]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911790-46-0 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-[[[2-[3-(aminocarbonyl)phenoxy]-1,1-dimethylethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




—NH<sub>2</sub>t

—Pr-i


RN 911790-59-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[methyl(phenylsulfonyl)amino]-5-[[[(2-thiazolylmethyl)amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911790-66-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(methylamino)carbonyl]amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911790-67-5 CAPLUS

CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[(1R)-1-phenylethyl]amino]carbonyl]-5-[[[(phenylmethyl)amino]carbonyl]amino]benzoyl]amino]propyl]-L-alanyl-N-ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911790-68-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1S)-2-[[[(1S)-2-[[1-[(ethylamino)carbonyl]propyl]amino]-1-methyl-2-oxoethyl]amino]-1-(phenylmethyl)ethyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911790-69-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1S)-2-[[[(1S)-2-[[1-[(ethylamino)carbonyl]propyl]amino]-1-methyl-2-oxoethyl]amino]-1-(phenylmethyl)ethyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1R)-1-phenylethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 911790-68-6

CMF C36 H48 N6 O6 S

Absolute stereochemistry.






CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 911790-75-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1S)-2-[[[(1S)-2-[[1-[(ethylamino)carbonyl]propyl]amino]-1-methyl-2-oxoethyl]amino]-1-(phenylmethyl)ethyl]-N'-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911790-76-6 CAPLUS


CN 1,3-Benzenedicarboxamide, N-[(1R)-1-(3-chlorophenyl)ethyl]-N'-[(1S)-2-[[[(1S)-2-[[1-[(ethylamino)carbonyl]propyl]amino]-1-methyl-2-oxoethyl]amino]-1-(phenylmethyl)ethyl]-5-[methyl(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911790-87-9 CAPLUS  
 CN 1,3-Benzenedicarboxamide, N-[(1S)-2-[[[(1S)-2-[[[(1S)-1-[[[(cyclopropylmethyl)amino]carbonyl]propyl]amino]-1-methyl-2-oxoethyl]amino]-1-(phenylmethyl)ethyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1R)-1-phenylethyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911790-88-0 CAPLUS  
 CN 1,3-Benzenedicarboxamide, N-[(1S)-2-[[[(1S)-1-[[[(1S)-1-[(ethylamino)carbonyl]-2-methylpropyl]amino]carbonyl]propyl]amino]-1-(phenylmethyl)ethyl]-5-(2-oxo-1-pyrrolidiny)]-N'-[(1R)-1-phenylethyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911790-89-1 CAPLUS  
 CN 1,3-Benzenedicarboxamide, N-[(1S)-2-[[[(1S)-1-[[[(1S)-1-[(ethylamino)carbonyl]-2-methylpropyl]amino]carbonyl]propyl]amino]-1-(phenylmethyl)ethyl]-5-(2-oxo-1-pyrrolidiny)]-N'-[(1R)-1-phenylethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 911790-88-0  
 CMF C40 H52 N6 O5

Absolute stereochemistry.



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2




RN 911790-90-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 911790-91-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[[4-[(methylamino)carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 911790-92-6 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 911790-93-7 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911790-94-8 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[[4-(hydroxymethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 911790-95-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 911790-96-0 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[(3-cyanophenyl)methyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 911790-97-1 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[(4-methoxyphenyl)methyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 911790-98-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[[4-(aminosulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 911790-99-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A




PAGE 1-B




RN 911791-00-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-cyclopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 911791-01-0 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[(4-aminophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 911791-02-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[[4-(1-pyrrolidinylmethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 911791-03-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[[4-[[[(dimethylamino)carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 911791-04-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-pyrazinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A






RN 911791-10-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[[4-[[aminocarbonyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911791-11-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 911791-12-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-cyclobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 911791-13-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 911791-14-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 911791-15-6 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[[4-(1H-imidazol-2-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 911791-16-7 CAPLUS  
 CN L-Valinamide, N-[[2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-([1,1'-biphenyl]-4-ylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A






PAGE 1-B




RN 911791-17-8 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[[4-(aminocarbonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 911791-18-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[[4-(acetamino)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 911791-19-0 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[[4-[[[(methylamino)carbonyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 911791-20-3 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-(1-cyclopropylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 911791-21-4 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 911791-22-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 911791-23-6 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-cyclohexyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 911791-24-7 CAPLUS  
 CN L-Valinamide, N-[[[2S]-2-[[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-(3-pyridinylmethyl)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






RN 911791-25-8 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911791-26-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[(3-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 911791-27-0 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 911791-28-1 CAPLUS  
 CN 1,3-Benzenedicarboxamide, N-[(1R)-1-(3-chlorophenyl)ethyl]-N'-[(1S)-1-[[[(1S)-1-methyl-2-[[[(1S)-2-methyl-1-(1-pyrrolidinylcarbonyl)propyl]amino]-2-oxoethyl]amino]methyl]-2-phenylethyl]-5-[methyl(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911791-29-2 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-butyryl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911791-30-5 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 911791-31-6 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 911791-32-7 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 911791-33-8 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 911791-34-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-(2,2-dimethylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 911791-35-0 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 911791-36-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-2-thiazolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 911791-37-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 911791-38-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—Cl

RN 911791-39-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

-Cl


RN 911791-40-7 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 911791-41-8 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911791-42-9 CAPLUS  
 CN L-Valine, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-, 2-phenylhydrazide (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 911791-43-0 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-2-propynyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 911791-44-1 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-3-isoxazolyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A






PAGE 1-B




RN 911791-45-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 911791-46-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-(2-cyano-3-thienyl)-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911791-50-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[[2'-(aminocarbonyl)-5-[[[(1R)-1-phenylethyl]amino]carbonyl][1,1'-biphenyl]-3-yl]carbonyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911791-51-0 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[[2'-cyano-5-[[[(1R)-1-phenylethyl]amino]carbonyl][1,1'-biphenyl]-3-yl]carbonyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911791-52-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[[2'-cyano-5-[[[(2-phenylethyl)amino]carbonyl][1,1'-biphenyl]-3-yl]carbonyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI)


(CA INDEX NAME)

Absolute stereochemistry.




RN 911791-53-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[[2'-cyano-5-[[methyl(2-phenylethyl)amino]carbonyl][1,1'-biphenyl]-3-yl]carbonyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911791-54-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[[5-[[[(1R)-1-(4-bromophenyl)ethyl]amino]carbonyl]-2'-cyano[1,1'-biphenyl]-3-yl]carbonyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911791-55-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[[2'-cyano-5-[[[(2R)-2-phenylpropyl]amino]carbonyl][1,1'-biphenyl]-3-yl]carbonyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911791-56-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[[2'-cyano-5-[(phenylmethyl)propylamino]carbonyl][1,1'-biphenyl]-3-yl]carbonyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911791-57-6 CAPLUS

911/91-57-6 CAPLOS  
L-Valinamide, N-[ (2S)-2-[[[2'-cyano-5-[(2-thiazolyl)methyl]amino]carbonyl]  
CN (1,1'-biphenyl)-3-yl]carbonyl]amino-3-phenylpropyl]-L-alanyl-N-ethyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911791-58-7 CAPLUS


L-Valinamide, N-[[[5-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-2'-cyano[1,1'-biphenyl]-3-yl]carbonyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911791-59-8 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[[2'-cyano-5-[[[(3-phenylpropyl)amino]carbonyl][1,1'-biphenyl]-3-yl]carbonyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 911791-60-1 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[[2'-cyano-5-[[[(2,2,2-trifluoro-1-phenylethyl)amino]carbonyl][1,1'-biphenyl]-3-yl]carbonyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911791-61-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[[2'-cyano-5-[[[1-(3-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-3-yl]carbonyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911791-62-3 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[[2'-cyano-5'-methyl-5-[[[(1R)-1-phenylethyl]amino]carbonyl][1,1'-biphenyl]-3-yl]carbonyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911791-63-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[[2'-cyano-3'-methoxy-5-[[[(1R)-1-phenylethyl]amino]carbonyl][1,1'-biphenyl]-3-yl]carbonyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911791-64-5 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[[2'-cyano-5'-methoxy-5-[[[(1R)-1-phenylethyl]amino]carbonyl][1,1'-biphenyl]-3-yl]carbonyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911791-65-6 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[[2'-cyano-3'-methyl-5-[[[(1R)-1-phenylethyl]amino]carbonyl][1,1'-biphenyl]-3-yl]carbonyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911791-67-8 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[[2'-cyano-5-[[[(1R)-1-phenylethyl]amino]carbonyl][1,1'-biphenyl]-3-yl]carbonyl]amino]-3-phenylpropyl]-L-alanyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 911791-69-0 CAPLUS

L-Valinamide, N-[[[2'-cyano-5-[[[(1R)-1-phenylethyl]amino]carbonyl][1,1'-biphenyl]-3-yl]carbonyl]amino]-3-phenylpropyl]-L-alanyl-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911791-70-3 CAPLUS

L-Valinamide, N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-seryl-N-methyl-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911791-75-8 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-(dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl)-5-[[[1-


(3-pyridinyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911791-76-9 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-bromophenyl)ethyl]amino]carbonyl]-5-(dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl)benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911791-77-0 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-(dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl)-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-(4-nitrophenyl)propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911791-78-1 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-(dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl)-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911791-79-2 CAPLUS

CN L-Valinamide, N-[(2S)-3-(4-aminophenyl)-2-[[3-(dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl)-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911791-84-9 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-(dihydro-5,5-dimethyl-2-oxo-2H-1,3-oxazin-3(4H)-yl)-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911791-87-2 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-bromophenyl)ethyl]amino]carbonyl]-5-(2-oxo-3-oxazolidinyl)benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911791-90-7 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-(2-oxo-3-oxazolidinyl)-5-[[[1-(3-pyridinyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911791-92-9 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-(5-methyl-2-oxo-3-oxazolidinyl)-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911791-95-2 CAPLUS


CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-bromophenyl)ethyl]amino]carbonyl]-5-(5-methyl-2-oxo-3-oxazolidinyl)benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911791-98-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-(5-methyl-2-oxo-3-oxazolidinyl)-5-[[[1-(3-pyridinyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911792-00-2 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-(4-methyl-2-oxo-3-oxazolidinyl)-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911792-02-4 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(4-bromophenyl)ethyl]amino]carbonyl]-5-(4-methyl-2-oxo-3-oxazolidinyl)benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911792-05-7 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-(4-methyl-2-oxo-3-oxazolidinyl)-5-[[[1-(3-pyridinyl)ethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911792-08-0 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-(2-oxo-3-oxazolidinyl)-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911792-09-1 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-(3-oxo-4-morpholinyl)-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911792-12-6 CAPLUS

CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[(phenylamino)carbonyl]amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 911792-20-6 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[[[(5-amino-1H-1,2,4-triazol-3-yl)methyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911792-21-7 CAPLUS

CN L-Valinamide, 4,4,5,5-tetradehydro-N-[(2S)-2-[[3-[methyl(methylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-norvalyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911792-22-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1S)-2-[[1-[[[(1S)-1-[(ethylamino)carbonyl]-2-methylpropyl]amino]carbonyl]-3,3,3-trifluoropropyl]amino]-1-


(phenylmethyl)ethyl]-5-[methyl(methylsulfonyl)amino]-N'--[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911792-23-9 CAPLUS  
CN L-Valinamide, N-[(2S)-3-phenyl-2-[[3-[[[1-(3-pyridinyl)ethyl]amino]carbonyl]-5-(tetrahydro-1,1-dioxido-2H-1,2,6-thiadiazin-2-yl)benzoyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911792-28-4 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[[2'-cyano-5-[[[(1R)-1-phenylethyl]amino]carbonyl][1,1'-biphenyl]-3-yl]carbonyl]amino]-3-(4-nitrophenyl)propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911792-31-9 CAPLUS

CN L-Valinamide, N-[(2S)-3-(4-aminophenyl)-2-[[[2'-cyano-5-[[[(1R)-1-phenylethyl]amino]carbonyl]]-1,1'-biphenyl]-3-yl]carbonyl]amino]propyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911792-32-0 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[[3-[methyl(methylsulfonyl)amino]-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-allothreonyl-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 911823-02-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-[[[(1R)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-(4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



IT 911789-32-7  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of peptide ethylenediamine derivs. for treatment of Alzheimer's disease)  
 RN 911789-32-7 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-(acetylamino)-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 911787-53-6P 911787-54-7P 911789-59-8P  
 911789-60-1P 911789-69-0P 911789-70-3P  
 911789-77-0P 911789-78-1P 911789-99-6P  
 911790-00-6P 911790-24-4P 911790-25-5P  
 911791-71-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of peptide ethylenediamine derivs. for treatment of Alzheimer's  
 disease)


RN 911787-53-6 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-(methoxycarbonyl)benzoyl]amino]-3-  
 phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911787-54-7 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[(3-carboxybenzoyl)amino]-3-phenylpropyl]-L-alanyl-  
 N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911789-59-8 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-chloro-5-(methoxycarbonyl)benzoyl]amino]-3-  
 phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911789-60-1 CAPLUS


CN L-Valinamide, N-[(2S)-2-[(3-carboxy-5-chlorobenzoyl)amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911789-69-0 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-(methoxycarbonyl)-5-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911789-70-3 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-carboxy-5-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911789-77-0 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-(methoxycarbonyl)-5-(tetrahydro-1,1-dioxido-2H-


1,2,6-thiadiazin-2-yl)benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911789-78-1 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-carboxy-5-(tetrahydro-1,1-dioxido-2H-1,2,6-thiadiazin-2-yl)benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 911789-99-6 CAPLUS  
CN L-Valinamide, N-[(2S)-2-[[3-[[[(dimethylamino)sulfonyl]methylamino]-5-(methoxycarbonyl)benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 911790-00-6 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-carboxy-5-[[[(dimethylamino)sulfonyl]methylamino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911790-24-4 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-(methoxycarbonyl)-5-[methyl(4-morpholinylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 911790-25-5 CAPLUS  
 CN L-Valinamide, N-[(2S)-2-[[3-carboxy-5-[methyl(4-morpholinylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl]-



(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 911791-71-4 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-(dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl)-5-[[[(1R)-1-phenylethyl]amino]carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:548753 CAPLUS

DN 145:211323

TI BACE-1 inhibition by a series of  $\psi$ [CH<sub>2</sub>NH] reduced amide isosteres

AU Coburn, Craig A.; Stachel, Shawn J.; Jones, Kristen G.; Steele, Thomas G.; Rush, Diane M.; DiMuzio, Jillian; Pietrak, Beth L.; Lai, Ming-Tain; Huang, Qian; Lineberger, Janet; Jin, Lixia; Munshi, Sanjeev; Holloway, M. Katharine; Espeseth, Amy; Simon, Adam; Hazuda, Daria; Graham, Samuel L.; Vacca, Joseph P.

CS Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA, 19486, USA

SO Bioorganic & Medicinal Chemistry Letters (2006), 16(14), 3635-3638  
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier B.V.

DT Journal

LA English

AB A series of  $\beta$ -site amyloid precursor protein cleaving enzyme (BACE-1)

inhibitors containing a  $\psi(\text{CH}_2\text{NH})$  reduced amide bond were synthesized. Incorporation of this reduced amide isostere as a non-cleavable peptide surrogate afforded inhibitors possessing low nanomolar potencies in both an enzymic and cell-based assay.


IT 827579-68-0P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(crystal structure; preparation of peptides containing reduced amide bond as BACE-1 inhibitors)

RN 827579-68-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-N'-[(1S)-1-[[[(1S)-1-methyl-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]methyl]-2-phenylethyl]-5-[methyl(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 827579-90-8P 827579-94-2P 827579-98-6P

827580-00-7P 827580-06-3P 827580-10-9P


827580-12-1P 905294-95-3P 905294-96-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of peptides containing reduced amide bond as BACE-1 inhibitors)

RN 827579-90-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1S)-1-[[[2-[(2-methylpropyl)amino]-2-oxoethyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827579-94-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-N'-[(1S)-1-

[[[(1S)-3-hydroxy-1-[[[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]-5-[methyl(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827579-98-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]-N'-[[[(1S)-1-[[[(1S)-1-[[[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]-5-[methyl(methylsulfonyl)amino]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827580-00-7 CAPLUS


CN 1,3-Benzenedicarboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]-N'-[[[(1S)-1-[[[(1S)-1-methyl-2-oxo-2-(phenylmethyl)amino]ethyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827580-06-3 CAPLUS  
 CN 1,3-Benzenedicarboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1S)-1-[[[(1S)-1-[[2-methylpropyl]amino]carbonyl]butyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827580-10-9 CAPLUS  
 CN 1,3-Benzenedicarboxamide, N-[(1S)-1-[[[(1S)-2-(ethylamino)-1-methyl-2-oxoethyl]amino]methyl]-2-phenylethyl]-N'-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827580-12-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1S)-1-[[[(1S)-2-(cyclopropylamino)-1-methyl-2-oxoethyl]amino]methyl]-2-phenylethyl]-N'-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 905294-95-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1S)-1-[[[(1S)-1-[[[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 905294-96-4 CAPLUS

CN L-Proline, N-[(2S)-2-[[[3-[[[(1R)-1-(4-fluorophenyl)ethyl]amino]carbonyl]-5-[methyl(methylsulfonyl)amino]benzoyl]amino]-3-phenylpropyl]-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:619408 CAPLUS

DN 143:286673

TI Efficient solid-phase synthesis of peptide-based phosphine ligands:  
Towards combinatorial libraries of selective transition metal catalysts

AU Christensen, Christian A.; Meldal, Morten

CS Carlsberg Laboratory, SPOCC-Centre, Valby, 2500, Den.

SO Chemistry--A European Journal (2005), 11(14), 4121-4131

CODEN: CEUJED; ISSN: 0947-6539

PB Wiley-VCH Verlag GmbH & Co. KGaA

DT Journal

LA English

OS CASREACT 143:286673

AB A new methodol. for the solid-phase synthesis of peptide-based phosphine ligands has been developed. Solid supported peptide scaffolds possessing either primary or secondary amines were synthesized using com. available Fmoc-protected amino acids (Fmoc = 9-fluorenylmethyloxycarbonyl) and readily available Fmoc-protected amino aldehydes for reductive alkylation, in standard solid-phase peptide synthesis (SPPS). Phosphine moieties were introduced by phosphinomethylation of the free amines as the final solid-phase synthetic step, immediately prior to complexation with palladium(II), thus avoiding tedious protection/deprotection of the phosphine moieties during the synthesis of the ligands. The extensive use of com. building blocks and standard SPPS makes this methodol. well suited for the generation of solid-phase combinatorial libraries of novel ligands. Furthermore, it is possible to generate several different phosphine ligand libraries for every peptide scaffold library synthesized, by functionalizing the scaffold libraries with different phosphine moieties. The synthesized ligands were characterized on solid support by conventional <sup>31</sup>P NMR spectroscopy and, cleaved from the support, as their phosphine oxides by HPLC, <sup>1</sup>H NMR, <sup>31</sup>P NMR and high resolution ESMS. Palladium(II) allyl complexes were generated from the resin bound ligands and to demonstrate their catalytic properties, palladium catalyzed asym. allylic substitution reactions were performed. Good yields and moderate enantioselectivity was obtained for the selected combination of catalysts and substrate, but most importantly the concept of this new methodol. was proven. Screening of ligand libraries should afford more selective catalysts.

IT 864080-71-7DP, resin-bound 864080-71-7P

864080-72-8DP, resin-bound 864080-72-8P

864080-73-9DP, resin-bound 864080-73-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(solid phase synthesis of peptide-based phosphine ligands for preparation of combinatorial libraries of selective transition metal catalysts)

RN 864080-71-7 CAPLUS

CN L-Phenylalanine, N-[(2S)-2-(benzoylamino)-3-phenylpropyl]-L-leucyl-L-prolyl-L-phenylalanyl-ψ(CH<sub>2</sub>-NH)-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 864080-71-7 CAPLUS

CN L-Phenylalanine, N-[(2S)-2-(benzoylamino)-3-phenylpropyl]-L-leucyl-L-prolyl-L-phenylalanyl-ψ(CH<sub>2</sub>-NH)-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 864080-72-8 CAPLUS


CN L-Phenylalanine, N-[(2S)-2-(benzoylamino)-3-phenylpropyl]-L-alanyl-L-prolyl-L-phenylalanyl-ψ(CH<sub>2</sub>-NH)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 864080-72-8 CAPLUS  
 CN L-Phenylalanine, N-[(2S)-2-(benzoylamino)-3-phenylpropyl]-L-alanyl-L-prolyl-L-phenylalanyl-ψ(CH<sub>2</sub>-NH)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 864080-73-9 CAPLUS  
 CN L-Phenylalanine, N-[(2S)-2-(benzoylamino)-3-phenylpropyl]-L-alanyl-L-alanyl-L-phenylalanyl-ψ(CH<sub>2</sub>-NH)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864080-73-9 CAPLUS  
 CN L-Phenylalanine, N-[(2S)-2-(benzoylamino)-3-phenylpropyl]-L-alanyl-L-alanyl-L-phenylalanyl-ψ(CH<sub>2</sub>-NH)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RE.CNT 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:55020 CAPLUS  
DN 142:148805  
TI N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of  
Alzheimer's disease  
IN Coburn, Craig A.; Stachel, Shawn J.; Vacca, Joseph P.  
PA Merck & Co., Inc., USA  
SO PCT Int. Appl., 38 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005004802	A2	20050120	WO 2004-US20234	20040625
	WO 2005004802	A3	20050922		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004255183	A1	20050120	US 2003-483992P	P 20030630
				AU 2004-255183	20040625
				US 2003-483992P	P 20030630
	CA 2529994	A1	20050120	WO 2004-US20234	W 20040625
				CA 2004-2529994	20040625
				US 2003-483992P	P 20030630
	EP 1641748	A2	20060405	WO 2004-US20234	W 20040625
				EP 2004-777003	20040625
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
				US 2003-483992P	P 20030630
	CN 1812963	A	20060802	WO 2004-US20234	W 20040625
				CN 2004-80018501	20040625
				US 2003-483992P	P 20030630
	US 2006161020	A1	20060720	WO 2004-US20234	W 20040625
				US 2005-563538	20051219
				US 2003-483992P	P 20030630
				WO 2004-US20234	W 20040625


OS MARPAT 142:148805  
AB The present invention is directed to compds. which are inhibitors of the beta-secretase enzyme and which are useful in the treatment or prevention of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the treatment of such diseases in which the beta-secretase enzyme is involved.  
IT 827579-68-0P 827579-74-8P 827579-79-3P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(N-alkyl phenylcarboxamide  $\beta$ -secretase inhibitors for treatment of

Alzheimer's disease)

RN 827579-68-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-N'-[(1S)-1-[[[(1S)-1-methyl-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]methyl]-2-phenylethyl]-5-[methyl(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827579-74-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(2-methylcyclopropyl)methyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1S)-1-[[[(1S)-1-[[[(2-methylpropyl)amino]carbonyl]butyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827579-79-3 CAPLUS

CN Benzamide, 3-[(1Z)-2-(2-methylcyclopropyl)ethenyl]-N-[(1S)-1-[[[(1S)-1-methyl-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]methyl]-2-phenylethyl]-5-[methyl(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



IT 827579-88-4 827579-90-8 827579-92-0  
 827579-94-2 827579-96-4 827579-98-6  
 827580-00-7 827580-04-1 827580-05-2  
 827580-06-3 827580-08-5 827580-10-9  
 827580-12-1 827580-14-3 827580-16-5  
 827580-18-7 827580-20-1 827580-22-3  
 827580-24-5 827580-26-7 827580-28-9  
 827580-30-3 827580-32-5 827580-33-6  
 827580-34-7 827580-35-8 827580-37-0  
 827580-38-1 827580-39-2 827580-40-5  
 827580-42-7 827580-44-9 827580-46-1  
 827580-47-2 827580-49-4 827580-50-7  
 827580-52-9 827580-53-0 827580-54-1  
 827580-55-2 827580-57-4 827580-59-6  
 827580-61-0 827580-63-2


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)

(N-alkyl phenylcarboxamide  $\beta$ -secretase inhibitors for treatment of  
 Alzheimer's disease)

RN 827579-88-4 CAPLUS

CN [1,1'-Biphenyl]-3,5-dicarboxamide, 2'-cyano-N-[1-(4-fluorophenyl)ethyl]-N'-  
 [(1S)-1-[[[(1S)-1-methyl-2-[(2-methylpropyl)amino]-2-  
 oxoethyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827579-90-8 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1S)-1-[[[2-[(2-methylpropyl)amino]-2-oxoethyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827579-92-0 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-N'-[(1S)-1-[[[(1S)-1-(hydroxymethyl)-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]methyl]-2-phenylethyl]-5-[methyl(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827579-94-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-N'-[(1S)-1-[[[(1S)-3-hydroxy-1-[[[2-[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]-5-[methyl(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827579-96-4 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-N'-[[(1S)-1-[[[(1R)-1-methyl-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]methyl]-2-phenylethyl]-5-[methyl(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN' 827579-98-6 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]-N'-[[(1S)-1-[[[(1S)-1-[[[(2-methylpropyl)amino]carbonyl]-3-(methylsulfonyl)propyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827580-00-7 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1S)-1-[[[(1S)-1-methyl-2-oxo-2-(phenylmethyl)amino]ethyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827580-04-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1S)-1-[[[(1S)-1-methyl-2-oxo-2-(1-pyrrolidinyl)ethyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827580-05-2 CAPLUS


CN 1,3-Benzenedicarboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1S)-1-[[[(1S)-1-methyl-2-oxo-2-(1-piperazinyl)ethyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827580-06-3 CAPLUS  
 CN 1,3-Benzenedicarboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]-N'-[(1S)-1-[[[(1S)-1-[[[(2-methylpropyl)amino]carbonyl]butyl]amino]methyl]-2-phenylethyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827580-08-5 CAPLUS  
 CN Benzamide, 3-[[[(2-methylcyclopropyl)methyl]amino]-5-[methyl(methylsulfonyl)amino]-N-[(1S)-1-[[[(1S)-1-[[[(2-methylpropyl)amino]carbonyl]butyl]amino]methyl]-2-phenylethyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827580-10-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1S)-1-[[[(1S)-2-(ethylamino)-1-methyl-2-oxoethyl]amino]methyl]-2-phenylethyl]-N'-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827580-12-1 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1S)-1-[[[(1S)-2-(cyclopropylamino)-1-methyl-2-oxoethyl]amino]methyl]-2-phenylethyl]-N'-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827580-14-3 CAPLUS

CN 1,3-Benzenedicarboxamide, N-[(1S)-1-[[[(1S)-2-[(cyanomethyl)amino]-1-methyl-2-oxoethyl]amino]methyl]-2-phenylethyl]-N'-[(1R)-1-(4-fluorophenyl)ethyl]-5-[methyl(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 827580-16-5 CAPLUS  
 CN Benzamide, 3-[(2-methylcyclopropyl)methoxy]-N-[(1S)-1-[[[(1S)-1-methyl-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]methyl]-2-phenylethyl]-5-[methyl(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827580-18-7 CAPLUS  
 CN [1,1'-Biphenyl]-3-carboxamide, 3'-chloro-5-[ethyl(ethylsulfonyl)amino]-N-[(1S)-1-[[[(1S)-1-[[[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827580-20-1 CAPLUS

CN [1,1'-Biphenyl]-3-carboxamide, 3'-chloro-5-[ethyl(propylsulfonyl)amino]-N-[(1S)-1-[[[(1S)-1-[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827580-22-3 CAPLUS

CN [1,1'-Biphenyl]-3-carboxamide, 3'-chloro-N-[(1S)-1-[[[(1S)-1-[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]-5-[propyl(propylsulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827580-24-5 CAPLUS


CN Benzamide, 3-[[[(dimethylamino)sulfonyl]methylamino]-5-[(1Z)-2-[(1S,2S)-2-methylcyclopropyl]ethenyl]-N-[(1S)-1-[[[(1S)-1-methyl-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 827580-26-7 CAPLUS  
 CN Benzamide, N-[(1S)-1-[[[(1S)-1-[[[4-fluorophenyl]amino]carbonyl]butyl]amino]methyl]-2-phenylethyl]-3-[(1Z)-2-[(1S,2S)-2-methylcyclopropyl]ethenyl]-5-[methyl(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



RN 827580-28-9 CAPLUS  
 CN [1,1'-Biphenyl]-3-carboxamide, 3'-chloro-5-[(ethylsulfonyl)(2-methylpropyl)amino]-N-[(1S)-1-[[[(1S)-1-[[[2-methylpropyl]amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827580-30-3 CAPLUS

CN [1,1'-Biphenyl]-3-carboxamide, 3'-chloro-5-[(ethylsulfonyl)propylamino]-N-[(1S)-1-[[[(1S)-1-[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827580-32-5 CAPLUS


CN Benzamide, 3-[[[(dimethylamino)sulfonyl]methylamino]-N-[(1S)-1-[[[(1S)-2-[(4-fluorophenyl)amino]-1-methyl-2-oxoethyl]amino]methyl]-2-phenylethyl]-5-[(1Z)-2-(2-methylcyclopropyl)ethenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 827580-33-6 CAPLUS  
 CN Benzamide, 3-[[[(dimethylamino)sulfonyl]methylamino]-5-[(2-methylcyclopropyl)methoxy]-N-[(1S)-1-[[[(1S)-1-[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 827580-34-7 CAPLUS  
 CN Benzamide, N-[(1S)-1-[[[(1S)-1-[(2-methoxyphenyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]-3-[(1Z)-2-(2-methylcyclopropyl)ethenyl]-5-methyl(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 827580-35-8 CAPLUS  
 CN [1,1'-Biphenyl]-3,5-dicarboxamide, 2'-cyano-N-[1-(4-fluorophenyl)ethyl]-N'-  
 [(1S)-1-[[[(1S)-1-[[2-methylpropyl]amino]carbonyl]propyl]amino]methyl]-2-  
 phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827580-37-0 CAPLUS  
 CN [1,1'-Biphenyl]-3,5-dicarboxamide, 2'-cyano-N,N-diethyl-N'-[(1S)-1-[[[(1S)-  
 1-methyl-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]methyl]-2-phenylethyl]-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827580-38-1 CAPLUS  
 CN [1,1'-Biphenyl]-3,5-dicarboxamide, 2'-cyano-N-methyl-N-(1-methylpropyl)-N'-[(1S)-1-[[[(1S)-1-[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827580-39-2 CAPLUS  
 CN [1,1'-Biphenyl]-3,5-dicarboxamide, 2'-cyano-N'-[(1S)-1-[[[(1S)-1-[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827580-40-5 CAPLUS  
 CN [1,1'-Biphenyl]-3-carboxamide, 2'-cyano-3'-fluoro-5-[[[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]carbonyl]-N-[(1S)-1-[[[(1S)-1-[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 827580-42-7 CAPLUS  
 CN [1,1'-Biphenyl]-3,5-dicarboxamide, 2'-cyano-3'-methoxy-N-methyl-N'-[(1S)-1-[[[(1S)-1-methyl-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]methyl]-2-phenylethyl]]-N-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827580-44-9 CAPLUS  
 CN Benzamide, 3-[[[(dimethylamino)sulfonyl]methylamino]-5-[(1Z)-2-(2-methylcyclopropyl)ethenyl]]-N-[(1S)-1-[[[(1S)-1-[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]]- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.






RN 827580-46-1 CAPLUS  
 CN [1,1'-Biphenyl]-2,3',5'-tricarboxamide, N3'-[1-(4-fluorophenyl)ethyl]-N5'-  
 [(1S)-1-[[[(1S)-1-[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-  
 phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827580-47-2 CAPLUS  
 CN [1,1'-Biphenyl]-3,5-dicarboxamide, 2'-cyano-N-methyl-N'-[(1S)-1-[[[(1S)-1-  
 methyl-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]methyl]-2-phenylethyl]-N-  
 propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827580-49-4 CAPLUS

827380-454 CAS E03  
CN [1,1'-Biphenyl]-3,5-dicarboxamide, 2'-cyano-N-methyl-N'--[(1S)-1-[[[(1S)-1-  
[[2-methylpropyl]amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]-N-  
propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827580-50-7 CAPLUS


[1,1'-Biphenyl]-3-carboxamide, 2'-cyano-5-[[[(2R)-2-(methoxymethyl)-1-pyrrolidiny]carbonyl]-N-[(1S)-1-[[[(1S)-1-[[[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 827580-52-9 CAPLUS  
 CN [1,1'-Biphenyl]-3,5-dicarboxamide, 2'-cyano-3'-fluoro-N-methyl-N'-[(1S)-1-  
 [[[1S)-1-[[[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-  
 phenylethyl]-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827580-53-0 CAPLUS  
 CN [1,1'-Biphenyl]-3,5-dicarboxamide, N-butyl-2'-cyano-N-(2-fluoroethyl)-N'-  
 [(1S)-1-[[[(1S)-1-[[[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-  
 phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827580-54-1 CAPLUS  
 CN [1,1'-Biphenyl]-3-carboxamide, 2'-cyano-5-[(3,3-difluoro-1-piperidiny]carbonyl]-N-[(1S)-1-[[[(1S)-1-[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 827580-55-2 CAPLUS  
 CN [1,1'-Biphenyl]-3-carboxamide, 2'-cyano-5-[(3-fluoro-1-piperidiny]carbonyl]-N-[(1S)-1-[[[(1S)-1-[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 827580-57-4 CAPLUS  
 CN [1,1'-Biphenyl]-3-carboxamide, 2'-cyano-5-[(4,4-difluoro-1-piperidiny]carbonyl]-N-[(1S)-1-[[[(1S)-1-[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 827580-59-6 CAPLUS  
 CN [1,1'-Biphenyl]-3-carboxamide, 2'-cyano-5-[(4-fluoro-1-piperidiny]carbonyl]-N-[(1S)-1-[[[(1S)-1-[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 827580-61-0 CAPLUS  
 CN [1,1'-Biphenyl]-3-carboxamide, 2'-cyano-5-[[[(3R)-3-fluoro-1-pyrrolidinyl]carbonyl]-N-[(1S)-1-[[[(1S)-1-[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 827580-63-2 CAPLUS  
 CN [1,1'-Biphenyl]-3-carboxamide, 2'-cyano-N-[(1S)-1-[[[(1S)-1-[(2-methylpropyl)amino]carbonyl]propyl]amino]methyl]-2-phenylethyl]-5-[[2-(phenylmethyl)-1-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:551538 CAPLUS

DN 139:101424

TI Preparation of substituted amino carboxamides for the treatment of Alzheimer's disease

IN Jagodzinska, Barbara; Warpehoski, Martha A.

PA Elan Pharmaceuticals, Inc., USA; Pharmacia &amp; Upjohn Company

SO PCT Int. Appl., 133 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003057721	A2	20030717	WO 2003-US326	20030106
	WO 2003057721	A3	20040325		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2002-345316P	P 20020104
				US 2002-350419P	P 20020118
	CA 2472617	A1	20030717	CA 2003-2472617	20030106
				US 2002-345316P	P 20020104
				US 2002-350419P	P 20020118
				WO 2003-US326	W 20030106
	AU 2003206413	A1	20030724	AU 2003-206413	20030106
				US 2002-345316P	P 20020104
				US 2002-350419P	P 20020118
				WO 2003-US326	W 20030106
	US 2003166580	A1	20030904	US 2003-337075	20030106
	US 6962934	B2	20051108		
				US 2002-345316P	P 20020104
				US 2002-350419P	P 20020118
	EP 1458745	A2	20040922	EP 2003-703711	20030106

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

			US 2002-345316P	P	20020104
			US 2002-350419P	P	20020118
			WO 2003-US326	W	20030106
JP 2005534614	T	20051117	JP 2003-558035		20030106
			US 2002-345316P	P	20020104
			US 2002-350419P	P	20020118
			WO 2003-US326	W	20030106
BR 2003006724	A	20060411	BR 2003-6724		20030106
			US 2002-345316P	P	20020104
			US 2002-350419P	P	20020118
			WO 2003-US326	W	20030106

OS MARPAT 139:101424

AB The invention relates to compds. R1CONR6CHR2CHR8NR5CHR3CONR4R7 [R1 is H, Q (aryl, heteroaryl, heterocyclyl, alkyl, etc.), -(CRR')1-6-X-Q (X = null, O, S, CO, SO2, NQ; R, R' = alkyl, alkylaryl, alkylheteroaryl); R2, R3 = (un)substituted alk(en)(yn)yl, cycloalkyl, cycloalkylalkyl, (hetero)aryl, heterocyclyl, aryl-, heteroaryl-, heterocyclylalkyl; R4 = H, (hetero)aryl, heterocyclyl, etc., these groups attached to a 1-3 carbon chain, diarylmethyl, (cyclo)alkyl, etc.; R5-R7 = H, CO2R9, where R9 = alkyl, Ph, benzyl, or phenethyl; R8 = H, (un)substituted alkyl] which are useful in treating Alzheimer's disease and similar diseases. These compds. include inhibitors of the  $\beta$ -secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A. beta peptide in a mammal. Thus, N-[(2S)-3-(3,5-difluorophenyl)-2-[[3-[(dipropylamino)carbonyl]-5-methylbenzoyl]amino]propyl]-L-alanyl-N1-isobutyl-L-valinamide was prepared by coupling of N-[(2S)-2-amino-3-(3,5-difluorophenyl)propyl]-L-alanyl-N1-isobutyl-L-valinamide (preparation given, claimed compound) with 3-[(dipropylamino)carbonyl]-5-methylbenzoic acid.

IT 557787-89-0P 557787-90-3P 557787-92-5P  
557787-93-6P 557787-94-7P 557787-97-0P  
557787-98-1P 557788-01-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted amino carboxamides for the treatment of Alzheimer's disease)

RN 557787-89-0 CAPLUS

CN L-Valinamide, N-[(2S)-2-[[3-[(dipropylamino)carbonyl]benzoyl]amino]-3-phenylpropyl]-L-alanyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 557787-90-3 CAPLUS

CN L-Valinamide, N-[(2S)-3-(3,5-difluorophenyl)-2-[[3-[(dipropylamino)carbonyl]-5-methylbenzoyl]amino]propyl]-L-alanyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 557787-92-5 CAPLUS

CN 1,3-Benzenedicarboxamide, N'-[(1S)-1-[(3,5-difluorophenyl)methyl]-2-[[[(1S)-1-methyl-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]ethyl]-5-methyl-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 557787-93-6 CAPLUS


CN L-Valinamide, N-[(2S)-3-(3,5-difluorophenyl)-2-[[3-[(dipropylamino)carbonyl]benzoyl]amino]propyl]-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 557787-94-7 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-(3,5-difluorophenyl)-2-[[3-  
 [(dipropylamino)carbonyl]benzoyl]amino]propyl]-L-alanyl-N-(2-methylpropyl)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 557787-97-0 CAPLUS  
 CN 1,3-Benzenedicarboxamide, N'-[(1S)-1-[(3,5-difluorophenyl)methyl]-2-[[[(1S)-  
 1-methyl-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]ethyl]-N,N-dipropyl-,  
 monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 557787-98-1 CAPLUS  
 CN 1,3-Benzenedicarboxamide, N'-[(1S)-1-[[[(1S)-1-methyl-2-[(2-methylpropyl)amino]-2-oxoethyl]amino]methyl]-2-phenylethyl]-N,N-dipropyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 557788-01-9 CAPLUS  
 CN L-Valinamide, N-[(2S)-3-(3,5-difluorophenyl)-2-[[3-[(dipropylamino)carbonyl]benzoyl]amino]propyl]-L-alanyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

```

L13 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1986:417829 CAPLUS
DN 105:17829
TI Inhibition of [3H]captopril binding by peptide analog angiotensin
    converting enzyme inhibitors
AU Toll, Lawrence; Almquist, Ronald G.
CS Life Sci. Div., SRI Int., Menlo Park, CA, 94025, USA
SO Biochemical and Biophysical Research Communications (1986), 135(3), 770-7
    CODEN: BBRCA9; ISSN: 0006-291X
DT Journal
LA English
AB Ketomethylene containing peptide analogs, I (R1 = PhCONH, phthalimide or
    cyclobutanecarbonyl Lys NH; R2 = H or Me; R3 = COOH or CONHOH; X = COCH2,
    CH2NH2, or CH(OH)CH2) modeled after a snake venom pentapeptide, have been
    shown to be potent angiotensin converting enzyme [9015-82-1] inhibitors.
    Although the most potent compds. are ≤5-times more potent than
    captopril [62571-86-2] in inhibiting angiotensin converting enzyme
    activity, they are relatively weak inhibitors of [3H]captopril binding to
    membrane bound angiotensin converting enzyme. This indicates that
    inhibition of [3H]captopril binding and enzymic activity is due to binding
    to distinct sites. These results suggest that the inhibitors bind to an
    addnl. site on the enzyme distinct from the captopril binding site.
    Structure-activity relations are briefly discussed.
IT 102778-07-4
    RL: BIOL (Biological study)
        (angiotensin-converting enzyme and captopril binding inhibition by)
RN 102778-07-4 CAPLUS
CN L-Proline, 1-[N-[2-(benzoylamino)-3-phenylpropyl]glycyl]- (9CI) (CA INDEX
    NAME)

```

O=C1CCCCN1C(=O)NCC(NC(=O)c2ccccc2)CCc3ccccc3

L13 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1985:221204 CAPLUS

DN 102:221204

TI Proline derivatives

PA Otsuka Pharmaceutical Factory, Inc., Japan

SO Jpn. Kokai Tokkyo Koho, 5 pp.


CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 59206344	A	19841122	JP 1983-82389	19830511
	JP 03054716	B	19910821		
AB	JP 1983-82389 19830511				
	Antihypertensive (no data) title compds. I [R, R1 = H, Ph, PhCH2O2C (Z), Bz; R2 = (un)substituted phenyl; R3 = alkyl; X = alkylene] were prepared. Thus, a mixture of 1.9 g (S)-BzNHCH(CH2Ph)CHO, 1.3 g H-L-Ala-L-Pro-OH HCl, 0.8 mL Et3N, and 400 mL MeOH was hydrogenated over 10% Pd/C to give 790 mg N-[(2S)-2-benzamido-3-phenylpropyl]-L-alanyl-L-proline.				
IT	82014-18-4P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	82014-18-4 CAPLUS				
CN	L-Proline, 1-[N-[2-(benzoylamino)-3-phenylpropyl]-L-alanyl]-, (S)- (9CI) (CA INDEX NAME)				



L13 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1985:20227 CAPLUS

DN 102:20227

TI Ketomethyldipeptides. II. Effect of modifications of the  $\alpha$ -aminoketone portion on inhibition of angiotensin converting enzyme

AU Gordon, E. M.; Natarajan, S.; Pluscec, Jelka; Weller, H. N.; Godfrey, J. D.; Rom, M. B.; Sabo, E. F.; Engebrecht, J.; Cushman, D. W.

CS Squibb Inst. Med. Res., Princeton, NJ, 08540, USA

SO Biochemical and Biophysical Research Communications (1984), 124(1), 148-55

CODEN: BBRCA9; ISSN: 0006-291X


DT Journal

LA English

AB The consequences of chemical modifications of the  $\alpha$ -aminoketone moiety of ketomethyldipeptides on angiotensin-converting enzyme (ACE) inhibition are reported. Within the series of compds. examined, the optimal structural backbone formulation for inhibition of ACE is represented by I. Introduction of a Sar-Pro C-terminal dipeptide (where Sar is sarcosine) in


this system, in contrast to other inhibitor classes, is compatible with potent inhibitory activity. Other structure-activity relationships for ketomethyldipeptides and related derivs. are presented, and speculations on possible modes of binding of these inhibitors to ACE, and on the question of ketone rehybridization are offered.

IT 82014-18-4  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (angiotensin-converting enzyme inhibition by)  
 RN 82014-18-4 CAPLUS  
 CN L-Proline, 1-[N-[2-(benzoylamino)-3-phenylpropyl]-L-alanyl]-, (S)- (9CI)  
 (CA INDEX NAME)



L13 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1983:161152 CAPLUS  
 DN 98:161152  
 TI Synthesis and biological activity of an amino analog of a tripeptide inhibitor of angiotensin-converting enzyme  
 AU Almquist, Ronald G.; Christie, Pamela H.; Chao, Wanru; Johnson, Howard L.  
 CS Bio-Org. Chem. Lab., SRI Int., Menlo Park, CA, 94025, USA  
 SO Journal of Pharmaceutical Sciences (1983), 72(1), 63-7  
 CODEN: JPMSAE; ISSN: 0022-3549  
 DT Journal  
 LA English  
 AB Title tripeptide analog (S)-BzNHCH(CH<sub>2</sub>Ph)CH<sub>2</sub>-Gly-L-Pro-OH (I) was prepared by coupling (S)-BzNHCH(CH<sub>2</sub>Ph)CH<sub>2</sub>N(Fmoc)CH<sub>2</sub>R (II; Fmoc = 9-fluorenylmethoxycarbonyl, R = CO<sub>2</sub>H) with H-L-Pro-OCH<sub>2</sub>Ph by DCC/1-hydroxybenzotriazole, debenzylating the resulting (S)-BzNHCH(CH<sub>2</sub>Ph)CH<sub>2</sub>N(Fmoc)CH<sub>2</sub>CO-L-Pro-OR<sub>1</sub> (III, R<sub>1</sub> = CH<sub>2</sub>Ph) by hydrogenolysis, and Fmoc-deblocking the resulting III (R<sub>1</sub> = H) by liquid NH<sub>3</sub>. Z-L-Phe-Gly-OH (Z = PhCH<sub>2</sub>O<sub>2</sub>C) was reduced by BH<sub>3</sub> to give (S)-ZNHCH(CH<sub>2</sub>Ph)CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>OH, which was treated with Fmoc Cl to give (S)-ZNHCH(CH<sub>2</sub>Ph)CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>OH, which was Z-deblocked and then acylated with BzCl to give II (R = CH<sub>2</sub>OH), which was oxidized by CrO<sub>3</sub> to give II (R = CO<sub>2</sub>H). I inhibited angiotensin-converting enzyme with an I<sub>50</sub> of 620 μM as compared with an I<sub>50</sub> of 9.6 μM for Bz-Phe-Gly-Pro-OH. A model of the active site of the above enzyme is proposed.  
 IT 85304-30-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and acetylation and angiotensin-converting enzyme-inhibiting activity of)  
 RN 85304-30-9 CAPLUS  
 CN L-Proline, 1-[N-[2-(benzoylamino)-3-phenylpropyl]glycyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1982:402688 CAPLUS

DN 97:2688

TI Nonhydrolyzable tripeptide analogs as angiotensin-converting enzyme inhibitors

AU Natarajan, S.; Condon, M. E.; Nakane, M.; Reid, J.; Gordon, E. M.; Cushman, D. W.; Ondetti, M. A.

CS Squibb Inst. Med. Res., Princeton, NJ, 08540, USA

SO Pept.: Synth., Struct., Funct., Proc. Am. Pept. Symp., 7th (1981), 429-33. Editor(s): Rich, Daniel H.; Gross, Erhard. Publisher: Pierce Chem. Co., Rockford, Ill.

CODEN: 47LMAO

DT Conference

LA English

AB The hydrolyzable amide bond of suitable tripeptide substrates for angiotensin-converting enzyme (I) was modified to produce nonhydrolyzable moieties which acted as inhibitors. Modification of the amide bond to a ketomethylene moiety gave rise to the most potent inhibitor studied (II; PhCONHCH(CH2Ph)COCH2CH2CO-Pro-OH), with an I50 value (concentration for 50% of maximum inhibition) of 0.01  $\mu$ M. The increased potency of II is apparently caused by resistance to hydrolysis by I, the specific interaction of the C:O group and functional residues of the active site of I, or a combination of both. The nonhydrolyzable analogs synthesized retained a number of the I-binding functional groups of the peptide substrate: C-terminal carboxyl, ultimate amide bond, and side chains for secondary interactions. Modification of the amide bond to a secondary amine to produce reduction analogs yielded compds. which retained tetrahedral N in the transition state. Replacement of the amide bond with olefinic groups or ketomethylene groups (other than II) produced inhibitors of much poorer potency than II. An analog with a CH2-S replacing the amide was also synthesized.

IT 82014-18-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation and angiotensin-converting enzyme inhibition by)

RN 82014-18-4 CAPLUS

CN L-Proline, 1-[N-[2-(benzoylamino)-3-phenylpropyl]-L-alanyl]-, (S)- (9CI)  
(CA INDEX NAME)

